Development Collaboration With Sfj Pharmaceuticals For Pb2452

PhaseBio Pharmaceuticals

10/01/2020 14:32

Jan 10 (Reuters) - PhaseBio Pharmaceuticals Inc  PHAS.O :
    * PHASEBIO ANNOUNCES FINANCING AND CO-DEVELOPMENT
COLLABORATION
WITH SFJ PHARMACEUTICALS FOR PB2452
    * PHASEBIO PHARMACEUTICALS INC - PHASEBIO TO RECEIVE UP TO
$120
MILLION IN DEVELOPMENT FUNDING
    * PHASEBIO PHARMACEUTICALS INC - PHASEBIO RETAINS EXCLUSIVE
WORLDWIDE COMMERCIAL RIGHTS TO PB2452
    * PHASEBIO PHARMACEUTICALS- SFJ WILL FUND UP TO $90 MILLION
OF
DEVELOPMENT EXPENSES THROUGH END OF 2021 AND UP TO AN ADDITIONAL
$30 MILLION FOR PB2452
    * PHASEBIO PHARMACEUTICALS - WILL PAY SFJ SERIES OF ANNUAL
PAYMENTS OVER 7-8 YEARS AFTER RECEIPT OF REGULATORY APPROVALS IN
U.S., E.U. & CHINA/JAPAN
    * PHASEBIO PHARMACEUTICALS - AMOUNT TO BE REPAID BY CO WILL
NOT
EXCEED FIVE TIMES AMOUNT FUNDED BY SFJ

Source text for Eikon:  ID:nGNX1PKSpM 
Further company coverage:  PHAS.O 

 ((Briefs@thomsonreuters.com;))